Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evgen Pharma ( (GB:TCF) ) just unveiled an announcement.
TheraCryf has completed successful Good Manufacturing Practice production of 2.57kg of clinical-grade drug substance for its lead orexin-1 receptor antagonist, Ox-1, clearing a key bottleneck ahead of planned Phase 1 trials in human volunteers. The high-yield batch was delivered three weeks early and met quality standards on first pass, underscoring process robustness, supporting patent-backed scalability and de-risking the transition from preclinical work to first-in-human studies.
The material will now be formulated into final drug product as the company completes a 28-day toxicology study, keeping regulatory submissions and clinic readiness on track for the third quarter of 2026. Positioned for the large and growing substance use disorder treatment market, projected to exceed US$70 billion by 2035, TheraCryf aims to leverage Ox-1’s potential best-in-class profile to secure value-accretive partnerships with larger pharmaceutical companies as it progresses into early clinical development.
Spark’s Take on TCF Stock
According to Spark, TipRanks’ AI Analyst, TCF is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash burn despite a debt-free balance sheet). Technicals are moderately supportive due to price strength versus moving averages, but the very overbought RSI raises near-term risk. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a UK-based biotechnology company focused on developing new medicines for addiction and other neuropsychiatric disorders, key areas of unmet need within central nervous system disease. Its lead programme is a novel orexin-1 receptor antagonist for addiction, alongside a dopamine transporter modulator for fatigue-related conditions and a legacy oncology programme in glioblastoma, all advanced via a capital-light, virtual development model.
Average Trading Volume: 4,036,625
Technical Sentiment Signal: Sell
Current Market Cap: £4.84M
For detailed information about TCF stock, go to TipRanks’ Stock Analysis page.